Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Geffriaud

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Lancet (London, England)|June 5, 1993
Inefficacy and toxicity of pefloxacin in focal and segmental glomerulosclerosis with steroid-resistant nephrotic syndromeC Geffriaud-Ricouard, P Jungers, D Chauveau, et al.
AIDS (London, England)|June 1, 1989
Genetic analysis of CR1 (the C3b complement receptor, CD35) expression on erythrocytes of HIV-infected individualsJ H Cohen, C Geffriaud, V Caudwell, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|January 1, 1993
Relation between serum IGF-I and anaemia in predialysis chronic renal failure patientsC Geffriaud-Ricouard, B D Pablo Ureña, J C Souberbielle, et al.
Urology|March 15, 2001
Postvoid residual urine in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: pooled analysis of eleven controlled studies with alfuzosinS A McNeill, T B Hargreave, C Geffriaud-Ricouard, et al.
Klinische Wochenschrift|September 3, 1991
Antigen specificities and clinical distribution of ANCA in kidney diseasesP Lesavre, L H Noël, D Chauveau, et al.
European Urology|January 1, 1997
Efficacy and safety of sustained-release alfuzosin 5 mg in patients with benign prostatic hyperplasia. ALGEBI Study GroupJ M Buzelin, S Roth, C Geffriaud-Ricouard, et al.
Advances in Experimental Medicine and Biology|January 1, 1993
Clinical significance of ANCA in 98 patientsC Geffriaud-Ricouard, L H Noël, D Chauveau, et al.
Neurourology and Urodynamics|January 1, 1996
Effect of intravenous alfuzosin on urethral pressure in patients with neurogenic bladder dysfunction. DORALI Study GroupM Perrigot, M C Delauche-Cavallier, G Amarenco, et al.
British Journal of Urology|June 1, 1997
Clinical uroselectivity: evidence from patients treated with slow-release alfuzosin for symptomatic benign prostatic obstructionJ M Buzelin, M C Delauche-Cavallier, S Roth, et al.
Clinical Nephrology|March 1, 1993
Clinical spectrum associated with ANCA of defined antigen specificities in 98 selected patientsC Geffriaud-Ricouard, L H Noël, D Chauveau, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Lancet (London, England)|June 5, 1993
Inefficacy and toxicity of pefloxacin in focal and segmental glomerulosclerosis with steroid-resistant nephrotic syndromeC Geffriaud-Ricouard, P Jungers, D Chauveau, et al.
AIDS (London, England)|June 1, 1989
Genetic analysis of CR1 (the C3b complement receptor, CD35) expression on erythrocytes of HIV-infected individualsJ H Cohen, C Geffriaud, V Caudwell, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|January 1, 1993
Relation between serum IGF-I and anaemia in predialysis chronic renal failure patientsC Geffriaud-Ricouard, B D Pablo Ureña, J C Souberbielle, et al.
Urology|March 15, 2001
Postvoid residual urine in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: pooled analysis of eleven controlled studies with alfuzosinS A McNeill, T B Hargreave, C Geffriaud-Ricouard, et al.
Klinische Wochenschrift|September 3, 1991
Antigen specificities and clinical distribution of ANCA in kidney diseasesP Lesavre, L H Noël, D Chauveau, et al.
European Urology|January 1, 1997
Efficacy and safety of sustained-release alfuzosin 5 mg in patients with benign prostatic hyperplasia. ALGEBI Study GroupJ M Buzelin, S Roth, C Geffriaud-Ricouard, et al.
Advances in Experimental Medicine and Biology|January 1, 1993
Clinical significance of ANCA in 98 patientsC Geffriaud-Ricouard, L H Noël, D Chauveau, et al.
Neurourology and Urodynamics|January 1, 1996
Effect of intravenous alfuzosin on urethral pressure in patients with neurogenic bladder dysfunction. DORALI Study GroupM Perrigot, M C Delauche-Cavallier, G Amarenco, et al.
British Journal of Urology|June 1, 1997
Clinical uroselectivity: evidence from patients treated with slow-release alfuzosin for symptomatic benign prostatic obstructionJ M Buzelin, M C Delauche-Cavallier, S Roth, et al.
Clinical Nephrology|March 1, 1993
Clinical spectrum associated with ANCA of defined antigen specificities in 98 selected patientsC Geffriaud-Ricouard, L H Noël, D Chauveau, et al.
Pageof 2